tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Manzanares C et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. 1998 Transplant. Proc. pmid:9636513
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Kamińska D et al. Significant infections after hand transplantation in a Polish population. 2014 Transplant. Proc. pmid:25380943
Frei U and Wagner K Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. 1994 Transplant. Proc. pmid:7527963
Youhua Z et al. Clinical study of FK 506 in renal transplant recipients. 2000 Transplant. Proc. pmid:11119900
TuÄŸcu M et al. Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report. 2015 Transplant. Proc. pmid:26093759
Klintmalm GB et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679828
Lane BC et al. Evaluation of calcineurin's role in the immunosuppressive activity of FK 506, related macrolactams, and cyclosporine. 1993 Transplant. Proc. pmid:7679829
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
Venkataramanan R et al. Pharmacokinetics of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721261
Regazzi MB et al. Interaction between FK 506 and diltiazem in an animal model. 1996 Transplant. Proc. pmid:8623215
Brook NR et al. Prograf produces a molecular environment favoring antifibrosis, an effect reversed by the addition of rapamune. 2005 Jan-Feb Transplant. Proc. pmid:15808577
Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. 1990 Transplant. Proc. pmid:1689897
Shitrit D et al. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. 2003 Transplant. Proc. pmid:12644073
Ma A et al. Immunological evaluation of combination therapy with tacrolimus and sirolimus on long-term allograft survival in nonhuman primates. 2005 Jan-Feb Transplant. Proc. pmid:15808578
Crespo-Leiro MG et al. Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy. 2002 Transplant. Proc. pmid:11959213
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Zhao YJ et al. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis. 2013 Jul-Aug Transplant. Proc. pmid:23953533
Qu W et al. Correlation Between Immunosuppressive Therapy and CD4(+) T-Cell Intracellular Adenosine Triphosphate Levels in Liver Transplant Recipients. Transplant. Proc. pmid:27569951
Ringe B et al. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. 1998 Transplant. Proc. pmid:9636573
Lopes CT et al. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. 2008 Transplant. Proc. pmid:18455036
Imamura M et al. FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules. 2000 Transplant. Proc. pmid:11120238
Kim SJ et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. 2004 Transplant. Proc. pmid:15518759
Schreiber SL et al. Immunophilin-ligand complexes as probes of intracellular signaling pathways. 1991 Transplant. Proc. pmid:1721293
Forsythe J Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group. 1999 Transplant. Proc. pmid:10576049
Ullman KS et al. Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. 1991 Transplant. Proc. pmid:1721294
Butt TR et al. Molecular basis of immunosuppressive drug action: regulation of steroid receptor-mediated transcription by FK 506. 1996 Transplant. Proc. pmid:8623486
Kawaoka T et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. 2015 Transplant. Proc. pmid:25891736
Burg M et al. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients. 2009 Transplant. Proc. pmid:20005359
Schneeberger H et al. Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center. 1998 Transplant. Proc. pmid:9636642
Yamazaki R et al. Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. 2009 Transplant. Proc. pmid:19545738
Gavlik A et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. 1997 Transplant. Proc. pmid:9365633
Spada M et al. Morphology of acute rejection and observation of lymphoproliferative hyperplastic reaction in FK 506 treated pigs after small bowel transplantation. 1994 Transplant. Proc. pmid:7518142
Foroncewicz B et al. Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. 2003 Transplant. Proc. pmid:14529924
Reggiani P et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. 2005 Transplant. Proc. pmid:15919435
Moreno Gonzales M et al. Sublingual Tacrolimus in Liver Transplantation: A Valid Option? Transplant. Proc. pmid:27569953
Moscicka M et al. The effect of cyclosporine and tacrolimus on indigenous bacterial flora in human skin grafts. 2003 Transplant. Proc. pmid:14529942
Bahra M et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. 2005 Transplant. Proc. pmid:15919436
Kai N et al. A study on the timing of immunologic priming in autoimmune insulitis in NOD mice. 1992 Transplant. Proc. pmid:1376511
Langrehr JM et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. 1995 Transplant. Proc. pmid:7533373
Kim SW et al. Decreased formation of nitric oxide in rats treated with FK506. 2003 Transplant. Proc. pmid:12591357
Kim HC et al. Primary immunosuppression with tacrolimus in renal transplantation: a single center experience. 2003 Transplant. Proc. pmid:12591370
Nakata S et al. Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. 1991 Transplant. Proc. pmid:1721325
Ennaifer R et al. Nodular hyperplasia of the gastrointestinal tract after liver transplantation: role of immunosuppressive therapy? A case report. 2015 Transplant. Proc. pmid:25891739
Maes BD and Vanrenterghem YF Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus. 2004 Transplant. Proc. pmid:15041305
Jonas S et al. Cyclosporine-based quadruple induction therapy versus tacrolimus-based dual immunosuppression after liver transplantation: ten-year follow-up. 2002 Transplant. Proc. pmid:12176459
Chen JW et al. Ten-year results of a randomised prospective study of FK506 versus cyclosporine in management of primary orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176460
Tsuchida Y et al. Vascularized bone marrow allotransplantation in rats prolongs a simultaneous skin allograft. 1997 Transplant. Proc. pmid:9142252
Costa A et al. Small bowel myoelectrical activity after transplantation in pigs: motility versus ACR score. 1997 Transplant. Proc. pmid:9142281
Wasiak D et al. Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report. 2016 Transplant. Proc. pmid:27496507
Fontana I et al. Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody. 2004 Transplant. Proc. pmid:15110640
Woodside KJ et al. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. 2005 Transplant. Proc. pmid:15919491
Sakamoto K et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. 1995 Transplant. Proc. pmid:7533434
Dahmen U et al. Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs. 2002 Transplant. Proc. pmid:12270412
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. 1991 Transplant. Proc. pmid:1721358
Nalesnik MA et al. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. 1991 Transplant. Proc. pmid:1703335
Takahara S et al. Excellent results following 3 years of tacrolimus immunosuppression in kidney transplantation recipients in Japan: overall analysis of more than 1000 patients. 2002 Transplant. Proc. pmid:12176500
Lo CM et al. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. 1998 Transplant. Proc. pmid:9838571
Reichenspurner H et al. Tacrolimus-based immunosuppressive protocols in lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083062
Khanna A et al. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123118
Alper G and Small SL Cerebrospinal fluid after organ transplantation. 1996 Transplant. Proc. pmid:8908142
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Schmidt RJ et al. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721390
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Tze WJ et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. 1991 Transplant. Proc. pmid:1721391
Bilbao I et al. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. 2001 Transplant. Proc. pmid:11377472
van Duijnhoven EM et al. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. 2002 Transplant. Proc. pmid:12176552
Castel MA et al. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine. 2011 Jul-Aug Transplant. Proc. pmid:21839245
Ji SM et al. Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy. 2007 Transplant. Proc. pmid:17580148
Gu B et al. Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. 2018 Transplant. Proc. pmid:29880353
Weinbroum AA et al. Lack of cumulative effect of tacrolimus and low flow on a rat isolated liver. 2001 Transplant. Proc. pmid:11543812
Zuckermann A et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083518
Ohdan H et al. Prolongation of hamster-to-rat liver xenograft survival by donor bone marrow augmentation. 1997 Feb-Mar Transplant. Proc. pmid:9123589
Meloni F et al. Monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of lung-transplanted patients treated with tacrolimus as rescue treatment for refractory acute rejection. 2003 Transplant. Proc. pmid:12826211
Boggs S et al. FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. 1991 Transplant. Proc. pmid:1721420
Ogawa N et al. Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. 1996 Transplant. Proc. pmid:8658710
Soran A et al. Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. 2000 Transplant. Proc. pmid:10812157
Formica RN et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. 2003 Transplant. Proc. pmid:12742475
Baran DA et al. Can initial tacrolimus trough levels be predicted from clinical variables? 2004 Transplant. Proc. pmid:15621157
Hasegawa A et al. Optimal use of tacrolimus in living donor renal transplantation in children. 2002 Transplant. Proc. pmid:12176635
El-Sabrout R et al. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. 2002 Transplant. Proc. pmid:12176636
Eun SC et al. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. 2013 Transplant. Proc. pmid:23769045
van den Berg AP et al. Prediction of the inhibition of IL-2 production by calcineurin inhibitors. 2001 Feb-Mar Transplant. Proc. pmid:11267197
Wu M et al. Cyclosporine and tacrolimus alter renin-angiotesin system in mouse medullary-thick ascending limb cultured cells. 2001 Feb-Mar Transplant. Proc. pmid:11267198
Liu W et al. Transfusion of endothelial cells with lentivirus-mediated expression of fas ligand prolonged survival of rat liver allograft. 2012 Transplant. Proc. pmid:22664023
Otto C et al. Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats. 1998 Transplant. Proc. pmid:9723426
Chen H et al. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9745497
Halloran PF et al. Calcineurin and the biological effect of cyclosporine and tacrolimus. 1998 Transplant. Proc. pmid:9723430
Matevossian E et al. Nitric oxide inhibition and consecutive Aspisol application show a prolonged survival of orthotopic transplanted livers in a rat model. 2008 Transplant. Proc. pmid:18555092
Walgenbach KJ et al. Upregulation of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. 1998 Transplant. Proc. pmid:9745501
Murio JE et al. Compassionate use of FK 506 in liver transplantation. 1995 Transplant. Proc. pmid:7544501
Thomson AW et al. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. 1991 Transplant. Proc. pmid:1721452
Mohsin N et al. Low tacrolimus dose requirements in renal transplant recipients in the omani population: implications for pharmacogenetics? 2005 Transplant. Proc. pmid:16213259
Sainsbury TS et al. Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. 1991 Transplant. Proc. pmid:1721453
Todo S et al. Effect of FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450416
Treede H et al. Incidence and spectrum of infections in lung transplanted patients: comparison of four different immunosuppressive protocols. 2001 Feb-Mar Transplant. Proc. pmid:11267444
Chen H et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9636419
Yoshimura R et al. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. 1991 Transplant. Proc. pmid:1703686
Hartwig T et al. Low-dose sirolimus and tacrolimus in kidney transplantation: first results of a single-center experience. 2001 Nov-Dec Transplant. Proc. pmid:11750383
Pridöhl O et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. 2001 Nov-Dec Transplant. Proc. pmid:11750384